15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Coherus BioSciences Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 627% above the current $1.38. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.20 next quarter toward $-0.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Coherus BioSciences Inc.
As of Sep, 2 of 2 firms rate CHRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CHRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.22 – $-0.19 · 2 analysts · -40% YoY
Next period, 2 analysts expect Coherus BioSciences Inc to earn $-0.20 a share (range $-0.22 – $-0.19), versus $-0.34 a year earlier. Full-year consensus is $-0.85, growing to $-0.63 the year after.
REVENUE · NEXT QUARTER
$18.3M
Range $16.5M – $21.7M · 2 analysts · +44% YoY
Revenue is expected to reach $18.3M (range $16.5M – $21.7M), +43.5% year-over-year. Full-year consensus is $60.8M, rising to $100.4M next year.
Top analysts covering Coherus BioSciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CHRS.
#1
Douglas Tsao
HC Wainwright & Co. · Rank #248
Buy
$7.00+409.1% to target
Overall win rate
35%
+ Follow
#2
Jay Olson
Oppenheimer · Rank #360
Buy
$10.00+627.3% to target
Overall win rate
33%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #428
Buy
$4.00+190.9% to target
Overall win rate
32%
+ Follow
#4
MN
Michael Nedelcovych
TD Cowen
Buy
No targeton CHRS
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Hold
$1.10-20.0% to target
Coverage
—
+ Follow
CHRS stock forecast FAQ
What is CHRS's average 12-month price target?+
The 2 analysts with a live target average $10.00 for Coherus BioSciences Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is CHRS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CHRS?+
2 analysts have an active rating on Coherus BioSciences Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CHRS?+
Among analysts who currently cover CHRS, Douglas Tsao of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #248). Their current call is Buy with a $7.00 target.
What is Coherus BioSciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.22 – $-0.19) across 2 analysts. Full-year EPS is projected at $-0.85, rising to $-0.63 the following year.
How much revenue is Coherus BioSciences Inc expected to report next quarter?+
Consensus revenue is $18.3M (range $16.5M – $21.7M). Full-year revenue is projected at $60.8M, growing to $100.4M next year.
Have analysts been upgrading or downgrading CHRS lately?+
As of Sep, 2 of 2 firms rate CHRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CHRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
